Gastritis

Leave a Comment / General Surgery, Stomach, Surgery / By

GAStritis











Overview

 

Gastritis is an inflammation of the stomach lining that can manifest suddenly as acute gastritis or develop gradually as chronic gastritis.

Causes:

  • Gastritis is often triggered by various factors, including:
    • Infection with the bacterium Helicobacter pylori
    • Regular use of specific pain relievers, such as NSAIDs (nonsteroidal anti-inflammatory drugs)
    • Excessive alcohol consumption

Symptoms:

  • Gastritis may present with several symptoms, including:
    • Stomach pain
    • Indigestion
    • Feeling full and bloated
    • Nausea
    • Vomiting

Treatment:

  • The treatment of gastritis is tailored to its underlying cause:
    • In many cases, antacids and other medications are prescribed to reduce stomach acid and relieve symptoms.
    • When H. pylori infection is the cause, a combination of antibiotics like clarithromycin and amoxicillin or metronidazole may be prescribed to eradicate the bacterium.
    • Lifestyle modifications, such as avoiding alcohol, NSAIDs, and managing stress, can help prevent gastritis and its complications.

Potential Complications:

  • If left untreated, gastritis can lead to:
    • Ulcers
    • An increased risk of stomach cancer
    • Other associated complications

Epidemiology of Gastritis

 

Gastritis, an inflammation of the stomach lining, has varying prevalence rates depending on its type, underlying causes, and geographical location. Here are some key epidemiological factors related to gastritis:

Acute Gastritis:

  • In the United States, acute gastritis affects approximately 8 out of every 1,000 people. It is often linked to short-term infections, alcohol consumption, and medication use.

Chronic Gastritis:

  • Chronic gastritis affects around 2 out of every 10,000 people in the United States. However, its prevalence is much higher in developing countries, especially when associated with H. pylori infection, affecting up to 50% of the population.

Atrophic Gastritis:

  • In the United States, the estimated prevalence of atrophic gastritis can be as high as 15%. This prevalence is likely even higher in populations with a higher baseline prevalence of H. pylori infection, including non-White racial and ethnic minorities and first-generation immigrants from countries with a high prevalence of H. pylori infections.

Gender and Age:

  • Gastritis can affect both men and women, but the prevalence may vary depending on the type and underlying cause. For example, H. pylori infection-associated gastritis is more common in men, while acute gastritis is more common in women.
  • The prevalence of H. pylori infection increases with age, with a significant percentage of adolescents in the United States infected, compared to nearly universal infection rates in developing countries by age 5.

Geographical Variation:

  • The prevalence of gastritis varies across regions. H. pylori infection is more common in Asia, developing countries, and areas with a high prevalence of gastric adenocarcinomas.
  • In the United States, H. pylori infection-associated gastritis is more common in African Americans, Hispanics, and the elderly compared to Whites.

Causes and Risk Factors of Gastritis

 

Gastritis, characterized by inflammation of the stomach lining, can be attributed to various causes and risk factors:

Infections:

  • Infection with Helicobacter pylori, a common bacterium, is a major cause of gastritis.
  • Other infections, including bacterial, viral, parasitic, and fungal infections, can also lead to acute gastritis.

Medications:

  • Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen can induce gastritis due to their potential to erode the stomach lining, a condition called erosive gastritis.

Substance Abuse:

  • Excessive alcohol consumption and the use of recreational drugs like cocaine can contribute to gastritis.

Physiological Stress:

  • Severe physiological stress resulting from major surgery, trauma, or critical illness can cause acute gastritis. The diversion of blood supply away from the digestive system during stress makes the stomach lining more susceptible to chemical damage.

Underlying Conditions:

  • Certain diseases and conditions increase the risk of gastritis, including autoimmune disorders where the immune system mistakenly attacks healthy cells, and chronic bile reflux, where bile flows back into the stomach and esophagus.

Cancer Treatments:

  • Treatments such as chemotherapy drugs and radiation for cancer can elevate the risk of gastritis.

Lifestyle Factors:

  • Lifestyle habits such as excessive alcohol consumption, smoking, and severe stress can also contribute to the development of gastritis.

Pathophysiology of Gastritis

 

Gastritis, characterized by inflammation of the stomach lining (gastric mucosa), arises from a disturbance in the equilibrium between aggressive and protective factors that maintain gastric lining integrity.

Acute Gastritis:

  • Acute gastritis is often triggered by various factors, including nonsteroidal anti-inflammatory drugs (NSAIDs), stress, bile reflux, radiation, alcohol abuse, cocaine addiction, and ischemic damage.
  • These triggers can lead to ulcers, hemorrhage, and erosion of the gastric mucosa.
  • The gastric mucosa becomes weakened or injured, permitting stomach acids to exacerbate damage and inflammation.

Chronic Gastritis:

  • Chronic gastritis frequently results from a persistent infection with Helicobacter pylori (H. pylori), a bacterium that can be transmitted through environmental factors or the fecal-oral route.
  • H. pylori infection causes an accumulation of chronic inflammatory cells, leading to active chronic gastritis.
  • A defining characteristic of chronic gastritis is an influx of lymphocytes and plasma cells into the gastric mucosa.
  • The gastric mucosa’s compromised state allows stomach acids to further harm and inflame the lining.

Consequences:

  • In both acute and chronic gastritis, gastric mucosal weakening or injury allows stomach acids to perpetuate damage, potentially leading to the development of digestive problems such as stomach ulcers.
  • In severe cases, chronic gastritis may increase the risk of stomach cancer.

Symptom Variability:

  • It is noteworthy that gastritis symptoms may not consistently align with the degree of inflammation observed histologically.
  • Many patients with histological evidence of gastritis remain asymptomatic, often diagnosed incidentally during endoscopy conducted for other purposes.

Signs and Symptoms of Gastritis

 

Gastritis, characterized by inflammation of the stomach lining, can manifest with a range of signs and symptoms. However, it’s crucial to acknowledge that some individuals with gastritis may remain asymptomatic. Common symptoms associated with gastritis include:

  1. Gnawing or burning ache or pain (indigestion) in the upper abdomen, which may worsen or improve with eating.
  2. Nausea.
  3. Vomiting.
  4. A sensation of fullness in the upper abdomen following meals.
  5. Abdominal bloating.
  6. A burning or gnawing sensation in the stomach, especially between meals or at night.
  7. Hiccups.
  8. Loss of appetite.
  9. Presence of blood in vomit or stool, indicating potential stomach lining bleeding.
  10. Tummy pain.
  11. Feeling full and bloated.
  12. Reduced appetite compared to usual.

Classification of Gastritis: Understanding the Variations

 

Gastritis, the inflammation of the stomach lining, can be classified based on several criteria, providing a comprehensive understanding of the condition:

Based on Acuity, Histology, or Etiology:

  • Gastritis can be categorized by factors such as the acuity of the condition (acute or chronic), the histological features of inflammation, or its underlying causes.

Classification Systems:

  • Various classification systems are used in clinical practice to categorize gastritis, including:
    • The Sydney System, which integrates topographical, morphological, and etiological information to generate clinically relevant diagnoses. It also includes a visual analogue scale for grading histopathologic features.
    • The OLGA (Operative Link on Gastritis Assessment) staging system, utilized for reporting gastric histology. It combines the atrophy score from biopsies with the topography of atrophy assessed through directed biopsy mapping.
    • The Kyoto classification of gastritis, which considers endoscopic characteristics associated with H. pylori infection and identifies gastric cancer risk factors. It encompasses 19 endoscopic findings related to H. pylori infection, gastritis, and gastric cancer risk.

Non-Atrophic or Atrophic Classification:

  • Gastritis can also be classified as non-atrophic or atrophic based on the presence of atrophy in the gastric mucosa.

Special or Distinctive Forms:

  • There are special or distinctive forms of gastritis classified according to unique clinical features and histological characteristics.
OLGA Classification

The OLGA (Operative Link on Gastritis Assessment) Staging System is a histological staging system for gastritis that is used to assess the risk of gastric cancer. The system is based on the extent and severity of gastric atrophy, which is a loss of the glands that produce stomach acid.

OLGA Staging System

The OLGA staging system is based on a score that is calculated from the extent and severity of gastric atrophy in two areas of the stomach: the antrum and the corpus. The score ranges from 0 to 4, with higher scores indicating a higher risk of gastric cancer.

OLGA Stage Extent of Gastric Atrophy Severity of Gastric Atrophy Risk of Gastric Cancer
0 No atrophy No atrophy Low
Ia Atrophy in less than 25% of the antrum Mild atrophy Low
Ib Atrophy in 25% to 49% of the antrum Mild atrophy Low-moderate
II Atrophy in 50% to 74% of the antrum Moderate atrophy Moderate
IIIa Atrophy in 75% to 99% of the antrum Mild or moderate atrophy Moderate-high
IIIb Atrophy in 75% to 99% of the antrum Severe atrophy High
IV Atrophy in 100% of the antrum Any severity of atrophy High

 Uses of the OLGA Staging System

The OLGA staging system is used to:

  • Assess the risk of gastric cancer in patients with chronic gastritis
  • Guide the surveillance of patients with chronic gastritis
  • Make treatment decisions for patients with chronic gastritis

Benefits of the OLGA Staging System

The OLGA staging system is a simple and reproducible method for assessing the risk of gastric cancer. The system is also well-validated and has been shown to be an effective predictor of gastric cancer risk.

Limitations of the OLGA Staging System

The OLGA staging system is based on the extent and severity of gastric atrophy, but other factors can also contribute to the risk of gastric cancer, such as Helicobacter pylori infection and smoking. Therefore, the OLGA staging system should not be used in isolation to assess the risk of gastric cancer.

The Kyoto classification of gastritis is an endoscopic classification system that is used to assess the severity of chronic gastritis and the risk of gastric cancer. It is based on five endoscopic findings:

  1. Atrophy: This is a loss of the glands in the stomach lining that produce acid. Atrophy is graded on a scale of 0 to 3, with 0 being no atrophy, 1 being mild atrophy, 2 being moderate atrophy, and 3 being severe atrophy.

  2. Intestinal metaplasia: This is the replacement of normal stomach tissue with intestinal-type tissue. Intestinal metaplasia is graded on a scale of 0 to 3, with 0 being no intestinal metaplasia, 1 being intestinal metaplasia confined to the antrum (the lower part of the stomach), 2 being intestinal metaplasia extending into the corpus (the upper part of the stomach), and 3 being extensive intestinal metaplasia.

     

  3. Enlarged folds: This is an increase in the size of the folds of the stomach lining. Enlarged folds are graded on a scale of 0 to 2, with 0 being no enlarged folds, 1 being mild enlarged folds, and 2 being severe enlarged folds.

  4. Nodularity: This is the presence of small, rounded bumps on the surface of the stomach lining. Nodularity is graded on a scale of 0 to 2, with 0 being no nodularity, 1 being mild nodularity, and 2 being severe nodularity.

  5. Diffuse redness: This is an increase in the redness of the stomach lining. Diffuse redness is graded on a scale of 0 to 2, with 0 being no diffuse redness, 1 being mild diffuse redness, and 2 being severe diffuse redness.

The total Kyoto score for each patient is calculated by adding up the scores for each of the five findings. A score of 0 indicates a normal stomach, a score of 2 or 3 indicates H. pylori-infected gastritis, and a score of 4 or 5 indicates gastritis at increased risk for gastric cancer.

The Sydney System is a classification system for gastritis that is based on the histological findings of gastric biopsies. It is the most widely used classification system for gastritis and is used to assess the severity of gastritis and the risk of gastric cancer.

The Sydney System grades gastritis into four categories:

  • No gastritis: There is no evidence of gastritis.

  • Non-atrophic gastritis: There is inflammation of the gastric mucosa, but there is no loss of gastric glands.

  • Atrophic gastritis: There is loss of gastric glands. Atrophic gastritis is further divided into three grades based on the extent of atrophy:

    • Mild atrophic gastritis: Loss of gastric glands in less than 25% of the biopsy specimen.
    • Moderate atrophic gastritis: Loss of gastric glands in 25% to 49% of the biopsy specimen.
    • Severe atrophic gastritis: Loss of gastric glands in 50% or more of the biopsy specimen.

  • Special forms of gastritis: These are types of gastritis that have a distinctive appearance and may be associated with an increased risk of gastric cancer. Special forms of gastritis include granulomatous gastritis, autoimmune gastritis, and Helicobacter pylori-associated gastritis.

Diagnosis

 

Gastritis, characterized by inflammation of the stomach lining, can be diagnosed through various methods, each offering specific insights into the condition. These diagnostic approaches include:

  1. Upper Gastrointestinal (GI) Endoscopy:

    • Utilizes an endoscope with a camera to visualize the upper GI tract, including the esophagus, stomach, and duodenum.
    • Allows for the collection of stomach lining biopsies, which are examined under a microscope to diagnose gastritis or identify its cause.

  2. Blood Tests:

    • May screen for alternative causes of gastritis or complications.
    • A Complete Blood Count (CBC) can detect anemia, including pernicious anemia related to poor Vitamin B12 absorption.

  3. Stool Tests:

    • Check for H. pylori infection and blood in the stool, indicating potential stomach bleeding.

  4. Urea Breath Test:

    • Evaluates H. pylori infection by having the patient ingest urea labeled with a unique carbon atom. If H. pylori is present, it converts urea into carbon dioxide, detectable in exhaled breath.

  5. Upper GI Series:

    • Utilizes x-rays and barium, a chalky liquid, to visualize the upper GI tract and identify gastritis signs.

  6. H. pylori Tests:

    • Diagnose H. pylori infection, a bacterium often responsible for gastritis and ulcers. Tests can involve breath or stool samples and sometimes tissue from the stomach.

  7. Gastric Tissue Biopsy and Culture:

    • Involves the removal of stomach tissue for examination.
    • Culture examines the tissue sample for bacteria and other disease-causing organisms.

  8. Emerging Tests:

    • Deep learning systems are in development to aid in classifying gastritis lesions, summarizing their characteristics, and alerting endoscopists to findings.

Differential Diagnosis 

 

Gastritis, marked by inflammation of the stomach lining, shares symptoms with various other conditions, making differential diagnosis crucial. When diagnosing gastritis, it’s important to consider these potentially similar conditions:

  1. Functional Dyspepsia:

    • Persistent or recurrent upper abdominal pain or discomfort with no identifiable cause, even after thorough evaluation.

  2. Peptic Ulcer Disease:

    • Sores on the stomach lining, upper small intestine, or esophagus, often causing abdominal pain that may be alleviated by eating or antacids.

  3. Gastric Cancer (Stomach Cancer):

    • May exhibit gastritis-like symptoms, including indigestion and stomach discomfort, but can also present with severe symptoms like unexplained weight loss and persistent vomiting.

  4. Cholecystitis:

    • Inflammation of the gallbladder, frequently due to gallstones, leading to severe upper right abdominal pain, nausea, vomiting, and fever.

  5. Zollinger-Ellison Syndrome:

    • Formation of tumors in the pancreas or duodenum, causing excessive gastrin production, resulting in peptic ulcers.

  6. Pancreatitis:

    • Inflammation of the pancreas causing upper abdominal pain, nausea, and vomiting, resembling gastritis.

  7. Gastroesophageal Reflux Disease (GERD):

    • Characterized by chronic acid reflux, causing symptoms like heartburn, regurgitation, and nausea.

  8. Crohn’s Disease:

    • An inflammatory bowel disease affecting any part of the gastrointestinal tract, including the stomach, leading to abdominal pain, diarrhea, weight loss, and fatigue.

  9. Gastrinoma:

    • A neuroendocrine tumor secreting gastrin, resulting in excess stomach acid production, recurrent peptic ulcers, and diarrhea.

  10. Gastric Adenocarcinoma and Primary Gastric Lymphoma:

    • Types of stomach cancer with symptoms akin to gastritis, such as abdominal pain, nausea, vomiting, and weight loss.

  11. Other Conditions:

    • Diseases of the biliary system, liver failure, renal failure, respiratory failure, sepsis, shock, and infections like syphilis and tuberculosis can mimic gastritis.

Treatment 

 

The treatment of gastritis depends on its underlying cause, and various approaches are employed:

  1. Acute Gastritis (NSAIDs or Alcohol-Induced):

    • Discontinue NSAID or alcohol use as a primary step.
    • Full-dose treatment with H2-receptor antagonists, omeprazole, or misoprostol can heal NSAID-induced ulcers, even if NSAID therapy continues.
    • For alcoholic gastritis, quitting or reducing alcohol consumption is essential as part of the treatment plan.

  2. H. pylori-Induced Gastritis:

    • Typically treated with a combination of antibiotics, such as clarithromycin and amoxicillin or metronidazole, to eradicate the bacterium.
    • Often combined with acid-blocking drugs like proton pump inhibitors (PPIs) or histamine (H-2) blockers.

  3. Symptomatic Relief:

    • Over-the-counter (OTC) medications like proton pump inhibitors (PPIs) or antacids such as Pepto Bismol® can help soothe irritation and neutralize stomach acid, providing relief while the stomach heals.

  4. Alcoholic Gastritis:

    • Treatment may include antibiotics to control certain GI bacteria, proton pump inhibitors, other acid reduction medications, antacids to neutralize acid production, and probiotics to promote helpful gastric bacteria.

  5. Chronic Gastritis:

    • Specific treatments can cure some underlying conditions causing chronic gastritis.
    • For conditions that aren’t curable, long-term treatments aim to reduce the inflammation they cause.

  6. NSAID-Induced Gastritis:

    • Strategies may include coprescription of a gastroprotective drug, use of selective COX-2 inhibitors, and eradication of H. pylori.

Treatment for Helicobacter pylori (H. pylori) Infection

The treatment for H. pylori infection typically involves a combination of antibiotics and a proton pump inhibitor (PPI). Here are some key aspects of H. pylori treatment:

  1. Standard Triple Therapy (STT):

    • Consists of a PPI, amoxicillin, and clarithromycin.
    • Effectiveness has been decreasing due to antibiotic resistance.

  2. Alternative Regimens:

    • Quadruple Therapy: Includes a PPI, tetracycline, metronidazole, and a bismuth salt. Effective even in areas with high antibiotic resistance.
    • Bismuth Quadruple Therapy: Combines two antibiotics (tetracycline and metronidazole), bismuth, and a PPI.

  3. Treatment Duration:

    • Duration is crucial, with a 14-day course of standard triple therapy being superior to a 10-day course.

  4. Assessing Treatment Success:

    • After completion of antibiotic therapy and withholding PPI therapy for one to two weeks, test for treatment success.
    • Methods include urea breath test, fecal antigen testing, or biopsy-based testing performed at least four weeks after treatment.

  5. Challenges:

    • No regimen achieves a 100% cure rate, and few have a 90% cure rate.
    • Antibiotic resistance and treatment failure may necessitate exploring novel therapies.

  6. Exploring Novel Therapies:

    • Probiotic supplementation, tailored therapy, novel agents, and nanotechnology are being investigated in cases of resistance or treatment failure.
    •  

Standard Triple Therapy (STT) :

  1. Proton pump inhibitor (PPI): This medication reduces stomach acid production, which helps to create an environment that is less hospitable to H. pylori bacteria. Examples of PPIs include lansoprazole (Prevacid), omeprazole (Prilosec), and pantoprazole (Protonix). The standard dose of a PPI for H. pylori treatment is 30-40 mg taken twice daily.

  2. Amoxicillin: This is a broad-spectrum antibiotic that is effective against H. pylori. The standard dose of amoxicillin for H. pylori treatment is 1 gram taken twice daily.

  3. Clarithromycin: This is another antibiotic that is effective against H. pylori. The standard dose of clarithromycin for H. pylori treatment is 500 mg taken twice daily.

STT is typically taken for 14 days. However, some studies have shown that shorter treatment regimens, such as 10 days or 7 days, may be just as effective.

Side effects of STT

STT is generally well-tolerated, but some people may experience side effects, such as:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Headache
  • Metallic taste in the mouth

Quadruple Therapy for H. pylori Infection

Quadruple therapy is a regimen used to treat Helicobacter pylori (H. pylori) infection. Here’s a common regimen along with important considerations:

Common Quadruple Therapy Regimen:

  • PPI (e.g., lansoprazole 30 mg) twice daily
  • Bismuth potassium citrate 220 mg twice daily
  • Tetracycline 500 mg four times daily
  • Metronidazole 400 mg four times daily
  • This regimen is typically administered for 14 days but can be adjusted based on the patient’s response and tolerance.

Effectiveness and Considerations:

  • Longer duration of PPI triple therapy improves the eradication rate of H. pylori.
  • Quadruple therapy is effective, even in areas with high antibiotic resistance.
  • It can be considered as an alternative first-line treatment when triple therapy is less effective due to resistance.

Side Effects:

  • Side effects can include dizziness, nausea, diarrhea, and increased bowel movement.
  • Treatment should be individualized, considering the patient’s overall health, potential side effects, and treatment compliance.

Prognosis of Gastritis

 

The prognosis of gastritis can vary based on its type, underlying cause, and individual patient factors. Here are some key points regarding the prognosis of gastritis:

Acute Gastritis:

  • Acute gastritis often clears spontaneously and is treatable once the underlying cause is determined.
  • Severe forms like phlegmonous gastritis have a high mortality rate, even with treatment.

Chronic Gastritis:

  • Prognosis is strongly related to the underlying cause. H. pylori-associated chronic gastritis may progress asymptomatically in some patients but can lead to complications like peptic ulcers or gastric malignancy.
  • Nonerosive gastritis can lead to complications over time, including mucosal atrophy and difficulties in nutrient absorption.
  • Atrophic gastritis prognosis depends on the severity, and there’s an increased risk of gastric malignancies in individuals with atrophy.

Overview

 

Gastritis is an inflammation of the stomach lining that can manifest suddenly as acute gastritis or develop gradually as chronic gastritis.

Causes:

  • Gastritis is often triggered by various factors, including:
    • Infection with the bacterium Helicobacter pylori
    • Regular use of specific pain relievers, such as NSAIDs (nonsteroidal anti-inflammatory drugs)
    • Excessive alcohol consumption

Symptoms:

  • Gastritis may present with several symptoms, including:
    • Stomach pain
    • Indigestion
    • Feeling full and bloated
    • Nausea
    • Vomiting

Treatment:

  • The treatment of gastritis is tailored to its underlying cause:
    • In many cases, antacids and other medications are prescribed to reduce stomach acid and relieve symptoms.
    • When H. pylori infection is the cause, a combination of antibiotics like clarithromycin and amoxicillin or metronidazole may be prescribed to eradicate the bacterium.
    • Lifestyle modifications, such as avoiding alcohol, NSAIDs, and managing stress, can help prevent gastritis and its complications.

Potential Complications:

  • If left untreated, gastritis can lead to:
    • Ulcers
    • An increased risk of stomach cancer
    • Other associated complications

Epidemiology of Gastritis

 

Gastritis, an inflammation of the stomach lining, has varying prevalence rates depending on its type, underlying causes, and geographical location. Here are some key epidemiological factors related to gastritis:

Acute Gastritis:

  • In the United States, acute gastritis affects approximately 8 out of every 1,000 people. It is often linked to short-term infections, alcohol consumption, and medication use.

Chronic Gastritis:

  • Chronic gastritis affects around 2 out of every 10,000 people in the United States. However, its prevalence is much higher in developing countries, especially when associated with H. pylori infection, affecting up to 50% of the population.

Atrophic Gastritis:

  • In the United States, the estimated prevalence of atrophic gastritis can be as high as 15%. This prevalence is likely even higher in populations with a higher baseline prevalence of H. pylori infection, including non-White racial and ethnic minorities and first-generation immigrants from countries with a high prevalence of H. pylori infections.

Gender and Age:

  • Gastritis can affect both men and women, but the prevalence may vary depending on the type and underlying cause. For example, H. pylori infection-associated gastritis is more common in men, while acute gastritis is more common in women.
  • The prevalence of H. pylori infection increases with age, with a significant percentage of adolescents in the United States infected, compared to nearly universal infection rates in developing countries by age 5.

Geographical Variation:

  • The prevalence of gastritis varies across regions. H. pylori infection is more common in Asia, developing countries, and areas with a high prevalence of gastric adenocarcinomas.
  • In the United States, H. pylori infection-associated gastritis is more common in African Americans, Hispanics, and the elderly compared to Whites.

Causes and Risk Factors of Gastritis

 

Gastritis, characterized by inflammation of the stomach lining, can be attributed to various causes and risk factors:

Infections:

  • Infection with Helicobacter pylori, a common bacterium, is a major cause of gastritis.
  • Other infections, including bacterial, viral, parasitic, and fungal infections, can also lead to acute gastritis.

Medications:

  • Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen can induce gastritis due to their potential to erode the stomach lining, a condition called erosive gastritis.

Substance Abuse:

  • Excessive alcohol consumption and the use of recreational drugs like cocaine can contribute to gastritis.

Physiological Stress:

  • Severe physiological stress resulting from major surgery, trauma, or critical illness can cause acute gastritis. The diversion of blood supply away from the digestive system during stress makes the stomach lining more susceptible to chemical damage.

Underlying Conditions:

  • Certain diseases and conditions increase the risk of gastritis, including autoimmune disorders where the immune system mistakenly attacks healthy cells, and chronic bile reflux, where bile flows back into the stomach and esophagus.

Cancer Treatments:

  • Treatments such as chemotherapy drugs and radiation for cancer can elevate the risk of gastritis.

Lifestyle Factors:

  • Lifestyle habits such as excessive alcohol consumption, smoking, and severe stress can also contribute to the development of gastritis.

Pathophysiology of Gastritis

 

Gastritis, characterized by inflammation of the stomach lining (gastric mucosa), arises from a disturbance in the equilibrium between aggressive and protective factors that maintain gastric lining integrity.

Acute Gastritis:

  • Acute gastritis is often triggered by various factors, including nonsteroidal anti-inflammatory drugs (NSAIDs), stress, bile reflux, radiation, alcohol abuse, cocaine addiction, and ischemic damage.
  • These triggers can lead to ulcers, hemorrhage, and erosion of the gastric mucosa.
  • The gastric mucosa becomes weakened or injured, permitting stomach acids to exacerbate damage and inflammation.

Chronic Gastritis:

  • Chronic gastritis frequently results from a persistent infection with Helicobacter pylori (H. pylori), a bacterium that can be transmitted through environmental factors or the fecal-oral route.
  • H. pylori infection causes an accumulation of chronic inflammatory cells, leading to active chronic gastritis.
  • A defining characteristic of chronic gastritis is an influx of lymphocytes and plasma cells into the gastric mucosa.
  • The gastric mucosa’s compromised state allows stomach acids to further harm and inflame the lining.

Consequences:

  • In both acute and chronic gastritis, gastric mucosal weakening or injury allows stomach acids to perpetuate damage, potentially leading to the development of digestive problems such as stomach ulcers.
  • In severe cases, chronic gastritis may increase the risk of stomach cancer.

Symptom Variability:

  • It is noteworthy that gastritis symptoms may not consistently align with the degree of inflammation observed histologically.
  • Many patients with histological evidence of gastritis remain asymptomatic, often diagnosed incidentally during endoscopy conducted for other purposes.

Signs and Symptoms of Gastritis

 

Gastritis, characterized by inflammation of the stomach lining, can manifest with a range of signs and symptoms. However, it’s crucial to acknowledge that some individuals with gastritis may remain asymptomatic. Common symptoms associated with gastritis include:

  1. Gnawing or burning ache or pain (indigestion) in the upper abdomen, which may worsen or improve with eating.
  2. Nausea.
  3. Vomiting.
  4. A sensation of fullness in the upper abdomen following meals.
  5. Abdominal bloating.
  6. A burning or gnawing sensation in the stomach, especially between meals or at night.
  7. Hiccups.
  8. Loss of appetite.
  9. Presence of blood in vomit or stool, indicating potential stomach lining bleeding.
  10. Tummy pain.
  11. Feeling full and bloated.
  12. Reduced appetite compared to usual.

Classification of Gastritis: Understanding the Variations

 

Gastritis, the inflammation of the stomach lining, can be classified based on several criteria, providing a comprehensive understanding of the condition:

Based on Acuity, Histology, or Etiology:

  • Gastritis can be categorized by factors such as the acuity of the condition (acute or chronic), the histological features of inflammation, or its underlying causes.

Classification Systems:

  • Various classification systems are used in clinical practice to categorize gastritis, including:
    • The Sydney System, which integrates topographical, morphological, and etiological information to generate clinically relevant diagnoses. It also includes a visual analogue scale for grading histopathologic features.
    • The OLGA (Operative Link on Gastritis Assessment) staging system, utilized for reporting gastric histology. It combines the atrophy score from biopsies with the topography of atrophy assessed through directed biopsy mapping.
    • The Kyoto classification of gastritis, which considers endoscopic characteristics associated with H. pylori infection and identifies gastric cancer risk factors. It encompasses 19 endoscopic findings related to H. pylori infection, gastritis, and gastric cancer risk.

Non-Atrophic or Atrophic Classification:

  • Gastritis can also be classified as non-atrophic or atrophic based on the presence of atrophy in the gastric mucosa.

Special or Distinctive Forms:

  • There are special or distinctive forms of gastritis classified according to unique clinical features and histological characteristics.
OLGA Classification

The OLGA (Operative Link on Gastritis Assessment) Staging System is a histological staging system for gastritis that is used to assess the risk of gastric cancer. The system is based on the extent and severity of gastric atrophy, which is a loss of the glands that produce stomach acid.

OLGA Staging System

The OLGA staging system is based on a score that is calculated from the extent and severity of gastric atrophy in two areas of the stomach: the antrum and the corpus. The score ranges from 0 to 4, with higher scores indicating a higher risk of gastric cancer.

OLGA Stage Extent of Gastric Atrophy Severity of Gastric Atrophy Risk of Gastric Cancer
0 No atrophy No atrophy Low
Ia Atrophy in less than 25% of the antrum Mild atrophy Low
Ib Atrophy in 25% to 49% of the antrum Mild atrophy Low-moderate
II Atrophy in 50% to 74% of the antrum Moderate atrophy Moderate
IIIa Atrophy in 75% to 99% of the antrum Mild or moderate atrophy Moderate-high
IIIb Atrophy in 75% to 99% of the antrum Severe atrophy High
IV Atrophy in 100% of the antrum Any severity of atrophy High

 Uses of the OLGA Staging System

The OLGA staging system is used to:

  • Assess the risk of gastric cancer in patients with chronic gastritis
  • Guide the surveillance of patients with chronic gastritis
  • Make treatment decisions for patients with chronic gastritis

Benefits of the OLGA Staging System

The OLGA staging system is a simple and reproducible method for assessing the risk of gastric cancer. The system is also well-validated and has been shown to be an effective predictor of gastric cancer risk.

Limitations of the OLGA Staging System

The OLGA staging system is based on the extent and severity of gastric atrophy, but other factors can also contribute to the risk of gastric cancer, such as Helicobacter pylori infection and smoking. Therefore, the OLGA staging system should not be used in isolation to assess the risk of gastric cancer.

The Kyoto classification of gastritis is an endoscopic classification system that is used to assess the severity of chronic gastritis and the risk of gastric cancer. It is based on five endoscopic findings:

  1. Atrophy: This is a loss of the glands in the stomach lining that produce acid. Atrophy is graded on a scale of 0 to 3, with 0 being no atrophy, 1 being mild atrophy, 2 being moderate atrophy, and 3 being severe atrophy.

  2. Intestinal metaplasia: This is the replacement of normal stomach tissue with intestinal-type tissue. Intestinal metaplasia is graded on a scale of 0 to 3, with 0 being no intestinal metaplasia, 1 being intestinal metaplasia confined to the antrum (the lower part of the stomach), 2 being intestinal metaplasia extending into the corpus (the upper part of the stomach), and 3 being extensive intestinal metaplasia.

     

  3. Enlarged folds: This is an increase in the size of the folds of the stomach lining. Enlarged folds are graded on a scale of 0 to 2, with 0 being no enlarged folds, 1 being mild enlarged folds, and 2 being severe enlarged folds.

  4. Nodularity: This is the presence of small, rounded bumps on the surface of the stomach lining. Nodularity is graded on a scale of 0 to 2, with 0 being no nodularity, 1 being mild nodularity, and 2 being severe nodularity.

  5. Diffuse redness: This is an increase in the redness of the stomach lining. Diffuse redness is graded on a scale of 0 to 2, with 0 being no diffuse redness, 1 being mild diffuse redness, and 2 being severe diffuse redness.

The total Kyoto score for each patient is calculated by adding up the scores for each of the five findings. A score of 0 indicates a normal stomach, a score of 2 or 3 indicates H. pylori-infected gastritis, and a score of 4 or 5 indicates gastritis at increased risk for gastric cancer.

The Sydney System is a classification system for gastritis that is based on the histological findings of gastric biopsies. It is the most widely used classification system for gastritis and is used to assess the severity of gastritis and the risk of gastric cancer.

The Sydney System grades gastritis into four categories:

  • No gastritis: There is no evidence of gastritis.

  • Non-atrophic gastritis: There is inflammation of the gastric mucosa, but there is no loss of gastric glands.

  • Atrophic gastritis: There is loss of gastric glands. Atrophic gastritis is further divided into three grades based on the extent of atrophy:

    • Mild atrophic gastritis: Loss of gastric glands in less than 25% of the biopsy specimen.
    • Moderate atrophic gastritis: Loss of gastric glands in 25% to 49% of the biopsy specimen.
    • Severe atrophic gastritis: Loss of gastric glands in 50% or more of the biopsy specimen.

  • Special forms of gastritis: These are types of gastritis that have a distinctive appearance and may be associated with an increased risk of gastric cancer. Special forms of gastritis include granulomatous gastritis, autoimmune gastritis, and Helicobacter pylori-associated gastritis.

The OLGA (Operative Link on Gastritis Assessment) Staging System is a histological staging system for gastritis that is used to assess the risk of gastric cancer. The system is based on the extent and severity of gastric atrophy, which is a loss of the glands that produce stomach acid.

OLGA Staging System

The OLGA staging system is based on a score that is calculated from the extent and severity of gastric atrophy in two areas of the stomach: the antrum and the corpus. The score ranges from 0 to 4, with higher scores indicating a higher risk of gastric cancer.

OLGA Stage Extent of Gastric Atrophy Severity of Gastric Atrophy Risk of Gastric Cancer
0 No atrophy No atrophy Low
Ia Atrophy in less than 25% of the antrum Mild atrophy Low
Ib Atrophy in 25% to 49% of the antrum Mild atrophy Low-moderate
II Atrophy in 50% to 74% of the antrum Moderate atrophy Moderate
IIIa Atrophy in 75% to 99% of the antrum Mild or moderate atrophy Moderate-high
IIIb Atrophy in 75% to 99% of the antrum Severe atrophy High
IV Atrophy in 100% of the antrum Any severity of atrophy High

 Uses of the OLGA Staging System

The OLGA staging system is used to:

  • Assess the risk of gastric cancer in patients with chronic gastritis
  • Guide the surveillance of patients with chronic gastritis
  • Make treatment decisions for patients with chronic gastritis

Benefits of the OLGA Staging System

The OLGA staging system is a simple and reproducible method for assessing the risk of gastric cancer. The system is also well-validated and has been shown to be an effective predictor of gastric cancer risk.

Limitations of the OLGA Staging System

The OLGA staging system is based on the extent and severity of gastric atrophy, but other factors can also contribute to the risk of gastric cancer, such as Helicobacter pylori infection and smoking. Therefore, the OLGA staging system should not be used in isolation to assess the risk of gastric cancer.

The Kyoto classification of gastritis is an endoscopic classification system that is used to assess the severity of chronic gastritis and the risk of gastric cancer. It is based on five endoscopic findings:

  1. Atrophy: This is a loss of the glands in the stomach lining that produce acid. Atrophy is graded on a scale of 0 to 3, with 0 being no atrophy, 1 being mild atrophy, 2 being moderate atrophy, and 3 being severe atrophy.

  2. Intestinal metaplasia: This is the replacement of normal stomach tissue with intestinal-type tissue. Intestinal metaplasia is graded on a scale of 0 to 3, with 0 being no intestinal metaplasia, 1 being intestinal metaplasia confined to the antrum (the lower part of the stomach), 2 being intestinal metaplasia extending into the corpus (the upper part of the stomach), and 3 being extensive intestinal metaplasia.

     

  3. Enlarged folds: This is an increase in the size of the folds of the stomach lining. Enlarged folds are graded on a scale of 0 to 2, with 0 being no enlarged folds, 1 being mild enlarged folds, and 2 being severe enlarged folds.

  4. Nodularity: This is the presence of small, rounded bumps on the surface of the stomach lining. Nodularity is graded on a scale of 0 to 2, with 0 being no nodularity, 1 being mild nodularity, and 2 being severe nodularity.

  5. Diffuse redness: This is an increase in the redness of the stomach lining. Diffuse redness is graded on a scale of 0 to 2, with 0 being no diffuse redness, 1 being mild diffuse redness, and 2 being severe diffuse redness.

The total Kyoto score for each patient is calculated by adding up the scores for each of the five findings. A score of 0 indicates a normal stomach, a score of 2 or 3 indicates H. pylori-infected gastritis, and a score of 4 or 5 indicates gastritis at increased risk for gastric cancer.

The Sydney System is a classification system for gastritis that is based on the histological findings of gastric biopsies. It is the most widely used classification system for gastritis and is used to assess the severity of gastritis and the risk of gastric cancer.

The Sydney System grades gastritis into four categories:

  • No gastritis: There is no evidence of gastritis.

  • Non-atrophic gastritis: There is inflammation of the gastric mucosa, but there is no loss of gastric glands.

  • Atrophic gastritis: There is loss of gastric glands. Atrophic gastritis is further divided into three grades based on the extent of atrophy:

    • Mild atrophic gastritis: Loss of gastric glands in less than 25% of the biopsy specimen.
    • Moderate atrophic gastritis: Loss of gastric glands in 25% to 49% of the biopsy specimen.
    • Severe atrophic gastritis: Loss of gastric glands in 50% or more of the biopsy specimen.

  • Special forms of gastritis: These are types of gastritis that have a distinctive appearance and may be associated with an increased risk of gastric cancer. Special forms of gastritis include granulomatous gastritis, autoimmune gastritis, and Helicobacter pylori-associated gastritis.

Diagnosis

 

Gastritis, characterized by inflammation of the stomach lining, can be diagnosed through various methods, each offering specific insights into the condition. These diagnostic approaches include:

  1. Upper Gastrointestinal (GI) Endoscopy:

    • Utilizes an endoscope with a camera to visualize the upper GI tract, including the esophagus, stomach, and duodenum.
    • Allows for the collection of stomach lining biopsies, which are examined under a microscope to diagnose gastritis or identify its cause.

  2. Blood Tests:

    • May screen for alternative causes of gastritis or complications.
    • A Complete Blood Count (CBC) can detect anemia, including pernicious anemia related to poor Vitamin B12 absorption.

  3. Stool Tests:

    • Check for H. pylori infection and blood in the stool, indicating potential stomach bleeding.

  4. Urea Breath Test:

    • Evaluates H. pylori infection by having the patient ingest urea labeled with a unique carbon atom. If H. pylori is present, it converts urea into carbon dioxide, detectable in exhaled breath.

  5. Upper GI Series:

    • Utilizes x-rays and barium, a chalky liquid, to visualize the upper GI tract and identify gastritis signs.

  6. H. pylori Tests:

    • Diagnose H. pylori infection, a bacterium often responsible for gastritis and ulcers. Tests can involve breath or stool samples and sometimes tissue from the stomach.

  7. Gastric Tissue Biopsy and Culture:

    • Involves the removal of stomach tissue for examination.
    • Culture examines the tissue sample for bacteria and other disease-causing organisms.

  8. Emerging Tests:

    • Deep learning systems are in development to aid in classifying gastritis lesions, summarizing their characteristics, and alerting endoscopists to findings.

Differential Diagnosis 

 

Gastritis, marked by inflammation of the stomach lining, shares symptoms with various other conditions, making differential diagnosis crucial. When diagnosing gastritis, it’s important to consider these potentially similar conditions:

  1. Functional Dyspepsia:

    • Persistent or recurrent upper abdominal pain or discomfort with no identifiable cause, even after thorough evaluation.

  2. Peptic Ulcer Disease:

    • Sores on the stomach lining, upper small intestine, or esophagus, often causing abdominal pain that may be alleviated by eating or antacids.

  3. Gastric Cancer (Stomach Cancer):

    • May exhibit gastritis-like symptoms, including indigestion and stomach discomfort, but can also present with severe symptoms like unexplained weight loss and persistent vomiting.

  4. Cholecystitis:

    • Inflammation of the gallbladder, frequently due to gallstones, leading to severe upper right abdominal pain, nausea, vomiting, and fever.

  5. Zollinger-Ellison Syndrome:

    • Formation of tumors in the pancreas or duodenum, causing excessive gastrin production, resulting in peptic ulcers.

  6. Pancreatitis:

    • Inflammation of the pancreas causing upper abdominal pain, nausea, and vomiting, resembling gastritis.

  7. Gastroesophageal Reflux Disease (GERD):

    • Characterized by chronic acid reflux, causing symptoms like heartburn, regurgitation, and nausea.

  8. Crohn’s Disease:

    • An inflammatory bowel disease affecting any part of the gastrointestinal tract, including the stomach, leading to abdominal pain, diarrhea, weight loss, and fatigue.

  9. Gastrinoma:

    • A neuroendocrine tumor secreting gastrin, resulting in excess stomach acid production, recurrent peptic ulcers, and diarrhea.

  10. Gastric Adenocarcinoma and Primary Gastric Lymphoma:

    • Types of stomach cancer with symptoms akin to gastritis, such as abdominal pain, nausea, vomiting, and weight loss.

  11. Other Conditions:

    • Diseases of the biliary system, liver failure, renal failure, respiratory failure, sepsis, shock, and infections like syphilis and tuberculosis can mimic gastritis.

Treatment 

 

The treatment of gastritis depends on its underlying cause, and various approaches are employed:

  1. Acute Gastritis (NSAIDs or Alcohol-Induced):

    • Discontinue NSAID or alcohol use as a primary step.
    • Full-dose treatment with H2-receptor antagonists, omeprazole, or misoprostol can heal NSAID-induced ulcers, even if NSAID therapy continues.
    • For alcoholic gastritis, quitting or reducing alcohol consumption is essential as part of the treatment plan.

  2. H. pylori-Induced Gastritis:

    • Typically treated with a combination of antibiotics, such as clarithromycin and amoxicillin or metronidazole, to eradicate the bacterium.
    • Often combined with acid-blocking drugs like proton pump inhibitors (PPIs) or histamine (H-2) blockers.

  3. Symptomatic Relief:

    • Over-the-counter (OTC) medications like proton pump inhibitors (PPIs) or antacids such as Pepto Bismol® can help soothe irritation and neutralize stomach acid, providing relief while the stomach heals.

  4. Alcoholic Gastritis:

    • Treatment may include antibiotics to control certain GI bacteria, proton pump inhibitors, other acid reduction medications, antacids to neutralize acid production, and probiotics to promote helpful gastric bacteria.

  5. Chronic Gastritis:

    • Specific treatments can cure some underlying conditions causing chronic gastritis.
    • For conditions that aren’t curable, long-term treatments aim to reduce the inflammation they cause.

  6. NSAID-Induced Gastritis:

    • Strategies may include coprescription of a gastroprotective drug, use of selective COX-2 inhibitors, and eradication of H. pylori.

Treatment for Helicobacter pylori (H. pylori) Infection

The treatment for H. pylori infection typically involves a combination of antibiotics and a proton pump inhibitor (PPI). Here are some key aspects of H. pylori treatment:

  1. Standard Triple Therapy (STT):

    • Consists of a PPI, amoxicillin, and clarithromycin.
    • Effectiveness has been decreasing due to antibiotic resistance.

  2. Alternative Regimens:

    • Quadruple Therapy: Includes a PPI, tetracycline, metronidazole, and a bismuth salt. Effective even in areas with high antibiotic resistance.
    • Bismuth Quadruple Therapy: Combines two antibiotics (tetracycline and metronidazole), bismuth, and a PPI.

  3. Treatment Duration:

    • Duration is crucial, with a 14-day course of standard triple therapy being superior to a 10-day course.

  4. Assessing Treatment Success:

    • After completion of antibiotic therapy and withholding PPI therapy for one to two weeks, test for treatment success.
    • Methods include urea breath test, fecal antigen testing, or biopsy-based testing performed at least four weeks after treatment.

  5. Challenges:

    • No regimen achieves a 100% cure rate, and few have a 90% cure rate.
    • Antibiotic resistance and treatment failure may necessitate exploring novel therapies.

  6. Exploring Novel Therapies:

    • Probiotic supplementation, tailored therapy, novel agents, and nanotechnology are being investigated in cases of resistance or treatment failure.
    •  

Standard Triple Therapy (STT) :

  1. Proton pump inhibitor (PPI): This medication reduces stomach acid production, which helps to create an environment that is less hospitable to H. pylori bacteria. Examples of PPIs include lansoprazole (Prevacid), omeprazole (Prilosec), and pantoprazole (Protonix). The standard dose of a PPI for H. pylori treatment is 30-40 mg taken twice daily.

  2. Amoxicillin: This is a broad-spectrum antibiotic that is effective against H. pylori. The standard dose of amoxicillin for H. pylori treatment is 1 gram taken twice daily.

  3. Clarithromycin: This is another antibiotic that is effective against H. pylori. The standard dose of clarithromycin for H. pylori treatment is 500 mg taken twice daily.

STT is typically taken for 14 days. However, some studies have shown that shorter treatment regimens, such as 10 days or 7 days, may be just as effective.

Side effects of STT

STT is generally well-tolerated, but some people may experience side effects, such as:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Headache
  • Metallic taste in the mouth

Quadruple Therapy for H. pylori Infection

Quadruple therapy is a regimen used to treat Helicobacter pylori (H. pylori) infection. Here’s a common regimen along with important considerations:

Common Quadruple Therapy Regimen:

  • PPI (e.g., lansoprazole 30 mg) twice daily
  • Bismuth potassium citrate 220 mg twice daily
  • Tetracycline 500 mg four times daily
  • Metronidazole 400 mg four times daily
  • This regimen is typically administered for 14 days but can be adjusted based on the patient’s response and tolerance.

Effectiveness and Considerations:

  • Longer duration of PPI triple therapy improves the eradication rate of H. pylori.
  • Quadruple therapy is effective, even in areas with high antibiotic resistance.
  • It can be considered as an alternative first-line treatment when triple therapy is less effective due to resistance.

Side Effects:

  • Side effects can include dizziness, nausea, diarrhea, and increased bowel movement.
  • Treatment should be individualized, considering the patient’s overall health, potential side effects, and treatment compliance.

Prognosis of Gastritis

 

The prognosis of gastritis can vary based on its type, underlying cause, and individual patient factors. Here are some key points regarding the prognosis of gastritis:

Acute Gastritis:

  • Acute gastritis often clears spontaneously and is treatable once the underlying cause is determined.
  • Severe forms like phlegmonous gastritis have a high mortality rate, even with treatment.

Chronic Gastritis:

  • Prognosis is strongly related to the underlying cause. H. pylori-associated chronic gastritis may progress asymptomatically in some patients but can lead to complications like peptic ulcers or gastric malignancy.
  • Nonerosive gastritis can lead to complications over time, including mucosal atrophy and difficulties in nutrient absorption.
  • Atrophic gastritis prognosis depends on the severity, and there’s an increased risk of gastric malignancies in individuals with atrophy.

Leave a Comment

Your email address will not be published. Required fields are marked *